Takeda Pharmaceutical (NYSE:TAK) Updates FY 2024 Earnings Guidance

Takeda Pharmaceutical (NYSE:TAK) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 3.330-3.330 for the period. The company issued revenue guidance of $30.1 billion-$30.1 billion.

Takeda Pharmaceutical Stock Performance

Shares of NYSE TAK traded down $0.28 during midday trading on Friday, hitting $13.43. The company’s stock had a trading volume of 458,441 shares, compared to its average volume of 2,011,953. The firm has a market capitalization of $42.72 billion, a price-to-earnings ratio of 23.18, a P/E/G ratio of 0.25 and a beta of 0.51. The company has a current ratio of 1.28, a quick ratio of 0.77 and a debt-to-equity ratio of 0.64. The stock has a fifty day moving average price of $13.31 and a 200 day moving average price of $13.88. Takeda Pharmaceutical has a one year low of $12.57 and a one year high of $15.08.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 6.49% and a return on equity of 10.00%. On average, research analysts forecast that Takeda Pharmaceutical will post 1.55 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.